European Medicines Agency updates on safety of Pradaxa

View source ↗

Summary

EMA updates safety information for Pradaxa (dabigatran) to reflect new risk signals and recommendations for monitoring and use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Venous Thromboembolism

Drugs mentioned

• Pradaxa (dabigatran etexilate)